Breathe Well Live Well
|
BRIEF-GSK submits application for Japanese approval of asthma drug
Reuters May 22 GlaxoSmithKline Plc : * Submits Japan regulatory application for mepolizumab in severe eosinophilic asthma. * Mepolizumab is an anti il-5 monoclonal antibody delivered in a 100mg fixed dose via a subcutaneous injection every four weeks. |
View full post on asthma – Google News
|
Glaxo submits new asthma drug application in Japan
MarketWatch LONDON–Pharmaceutical company GlaxoSmithKline PLC (GSK.LN) said Friday it has submitted a new drug application to the Japanese health ministry for mepolizumab, a drug used for treating a type of severe asthma. The application for mepolizumab has … Glaxo Submits Japan Application For Mepolizumab In Eosinophilic Asthma |
View full post on asthma – Google News
|
GSK Submits European, US Filings for Asthma Med
Drug Discovery & Development GlaxoSmithKline announced that it has filed regulatory submissions in the USA and Europe for mepolizumab for approval as a maintenance treatment for patients with severe eosinophilic asthma, identified by a blood eosinophil count of at least 150 cells … GSK Files for Approval of Mepolizumab in US, Europe for Eosinophilic Asthma GSK submits asthma biologic in US, EU GlaxoSmithKline heads to the FDA with its next big respiratory bet |
View full post on asthma – Google News
|
Acton Pharmaceuticals, Inc. Submits NDA Supplement to FDA for AEROSPAN(R …
MarketWatch (press release) AEROSPAN is a hydrofluoroalkane (HFA) propelled inhaled corticosteroid for the treatment of asthma, which will compete in the $7 billion US inhaled steroid … |
View full post on asthma – Google News